Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Evotec SE's 10-Year RORE % for the quarter that ended in Mar. 2026 was 145.43%.
The industry rank for Evotec SE's 10-Year RORE % or its related term are showing as below:
XSWX:EVT's 10-Year RORE % is ranked better than 96.26% of 668
companies
in the Drug Manufacturers industry
Industry Median: 6.27
vs XSWX:EVT: 145.43
Evotec SE (XSWX:EVT) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Evotec SE 10-Year RORE % Related Terms
Evotec SE 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Evotec SE's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:EVT vs ZTS, UTHR, VTRS: 10-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE 10-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Evotec SE's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Evotec SE (XSWX:EVT) has a 10-Year RORE % of 145.43 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Evotec SE and its competitors. According to the industry distribution chart, Evotec SE ranks #25 out of 668 companies in the Drug Manufacturers industry, placing it in the top 3.7%.
Is Evotec SE's 10-Year RORE % too high?
Evotec SE's current 10-Year RORE % is 145.43. The Drug Manufacturers industry median 10-Year RORE % is 6.27. Evotec SE's value of 145.43 is 2219.5% above this industry median. Based on the distribution chart, Evotec SE ranks #25 out of 668 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's 10-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #25 out of 668 companies for 10-Year RORE %. This places Evotec SE in the top 4% of its industry — outperforming the majority of peers. The industry median 10-Year RORE % is 6.27. Evotec SE's value of 145.43 is 2219.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.27, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current 10-Year RORE % of 145.43 is 2219.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current 10-Year RORE % is 145.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current 10-Year RORE % is 145.43 and 2219.5% above the Drug Manufacturers industry median of 6.27. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current 10-Year RORE % is 145.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (XSWX:EVT) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for XSWX:EVT:
10-Year RORE %: 145.43
GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
Industry Position: 2219.5% above the Drug Manufacturers median (#25 of 668)
No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score
Get the complete analysis for XSWX:EVT
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:EVT has been successfully added to your 
